Characteristics of 246 patients with previously untreated chronic-phase CML, by treatment arm
| . | Imatinib 400 mg/d, N = 123 . | Dasatinib 100 mg/d, N = 123 . | P* . |
|---|---|---|---|
| Median age, y (min-max) | 50 (19-89) | 47 (18-90) | .042 |
| Median WBC, 109/L (min-max) | 51.9 (0.3-401) | 89.0 (3.0-410) | .0097 |
| Median basophils, % (min-max) | 3 (0-18) | 3 (0-17) | .37 |
| Median platelets, 109/L (min-max) | 378 (109-1390) | 363 (100-1810) | .25 |
| Median BM blasts, % (min-max) | 1 (0-9) | 2 (0-12) | .56 |
| Sex, no. of patients (%) | .90 | ||
| Female | 51 (41) | 49 (40) | |
| Male | 72 (59) | 74 (60) | |
| Hasford risk category, no. of patients (%) | .73 | ||
| Low | 44 (36) | 44 (36) | |
| Intermediate | 45 (37) | 40 (33) | |
| High | 34 (28) | 39 (32) | |
| Performance status, no. of patients (%) | .36 | ||
| 0 | 76 (63) | 71 (58) | |
| 1 | 44 (36) | 47 (39) | |
| 2 | 1 (1) | 4 (3) | |
| NA | 2 (—) | 1 (—) | |
| Palpable splenomegaly, no. of patients (%) | .25 | ||
| Yes | 53 (44) | 63 (51) | |
| No | 68 (56) | 60 (49) | |
| NA | 2 (—) | 0 (—) | |
| Palpable hepatomegaly, no. of patients (%) | .75 | ||
| Yes | 4 (3) | 6 (5) | |
| No | 112 (97) | 111 (95) | |
| NA | 7 (—) | 6 (—) |
| . | Imatinib 400 mg/d, N = 123 . | Dasatinib 100 mg/d, N = 123 . | P* . |
|---|---|---|---|
| Median age, y (min-max) | 50 (19-89) | 47 (18-90) | .042 |
| Median WBC, 109/L (min-max) | 51.9 (0.3-401) | 89.0 (3.0-410) | .0097 |
| Median basophils, % (min-max) | 3 (0-18) | 3 (0-17) | .37 |
| Median platelets, 109/L (min-max) | 378 (109-1390) | 363 (100-1810) | .25 |
| Median BM blasts, % (min-max) | 1 (0-9) | 2 (0-12) | .56 |
| Sex, no. of patients (%) | .90 | ||
| Female | 51 (41) | 49 (40) | |
| Male | 72 (59) | 74 (60) | |
| Hasford risk category, no. of patients (%) | .73 | ||
| Low | 44 (36) | 44 (36) | |
| Intermediate | 45 (37) | 40 (33) | |
| High | 34 (28) | 39 (32) | |
| Performance status, no. of patients (%) | .36 | ||
| 0 | 76 (63) | 71 (58) | |
| 1 | 44 (36) | 47 (39) | |
| 2 | 1 (1) | 4 (3) | |
| NA | 2 (—) | 1 (—) | |
| Palpable splenomegaly, no. of patients (%) | .25 | ||
| Yes | 53 (44) | 63 (51) | |
| No | 68 (56) | 60 (49) | |
| NA | 2 (—) | 0 (—) | |
| Palpable hepatomegaly, no. of patients (%) | .75 | ||
| Yes | 4 (3) | 6 (5) | |
| No | 112 (97) | 111 (95) | |
| NA | 7 (—) | 6 (—) |
CML indicates chronic myeloid leukemia; WBC, white blood cell; NA, not available; and —, not calculated.
Two-sided P value from the Wilcoxon test (continuous variables) or the Fisher exact test (sex, organomegaly). P value from the Pearson χ2 test (Hasford risk category, performance status).